These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 31128886)
61. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. Xu R; Tao A; Zhang S; Deng Y; Chen G Sci Rep; 2015 Mar; 5():9284. PubMed ID: 25791171 [TBL] [Abstract][Full Text] [Related]
62. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. Shen J; Wong GL; Chan HL; Chan RS; Chan HY; Chu WC; Cheung BH; Yeung DK; Li LS; Sea MM; Woo J; Wong VW J Gastroenterol Hepatol; 2015 Jan; 30(1):139-46. PubMed ID: 25040896 [TBL] [Abstract][Full Text] [Related]
63. Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity. OʼSullivan TA; Oddy WH; Bremner AP; Sherriff JL; Ayonrinde OT; Olynyk JK; Beilin LJ; Mori TA; Adams LA J Pediatr Gastroenterol Nutr; 2014 May; 58(5):624-31. PubMed ID: 24345826 [TBL] [Abstract][Full Text] [Related]
64. The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes. Xia MF; Lin HD; Chen LY; Wu L; Ma H; Li Q; Aleteng Q; Hu Y; He WY; Gao J; Bian H; Li XY; Gao X Diabetologia; 2019 Apr; 62(4):644-654. PubMed ID: 30673802 [TBL] [Abstract][Full Text] [Related]
65. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322 [TBL] [Abstract][Full Text] [Related]
66. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Nobili V; Giorgio V; Liccardo D; Bedogni G; Morino G; Alisi A; Cianfarani S Eur J Endocrinol; 2014 Apr; 170(4):547-53. PubMed ID: 24412930 [TBL] [Abstract][Full Text] [Related]
68. Vitamin D Status and Bone Mineral Density in Obese Children with Nonalcoholic Fatty Liver Disease. Chang EJ; Yi DY; Yang HR J Korean Med Sci; 2015 Dec; 30(12):1821-7. PubMed ID: 26713058 [TBL] [Abstract][Full Text] [Related]
69. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Hagström H; Nasr P; Ekstedt M; Kechagias S; Önnerhag K; Nilsson E; Rorsman F; Sheikhi R; Marschall HU; Hultcrantz R; Stål P Scand J Gastroenterol; 2017 Feb; 52(2):159-165. PubMed ID: 27650916 [TBL] [Abstract][Full Text] [Related]
70. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282 [TBL] [Abstract][Full Text] [Related]
71. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. Kitamoto T; Kitamoto A; Ogawa Y; Honda Y; Imajo K; Saito S; Yoneda M; Nakamura T; Nakajima A; Hotta K J Hepatol; 2015 Aug; 63(2):494-502. PubMed ID: 25776890 [TBL] [Abstract][Full Text] [Related]
72. Maternal and Perinatal Risk Factors for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. Querter I; Pauwels NS; De Bruyne R; Dupont E; Verhelst X; Devisscher L; Van Vlierberghe H; Geerts A; Lefere S Clin Gastroenterol Hepatol; 2022 Apr; 20(4):740-755. PubMed ID: 33862225 [TBL] [Abstract][Full Text] [Related]
73. Pediatric fatty liver disease: role of ethnicity and genetics. Marzuillo P; Miraglia del Giudice E; Santoro N World J Gastroenterol; 2014 Jun; 20(23):7347-55. PubMed ID: 24966605 [TBL] [Abstract][Full Text] [Related]
75. Serum proteome assessment in nonalcoholic fatty liver disease in children: a preliminary study. Małecki P; Tracz J; Łuczak M; Figlerowicz M; Mazur-Melewska K; Służewski W; Mania A Expert Rev Proteomics; 2020; 17(7-8):623-632. PubMed ID: 32921203 [TBL] [Abstract][Full Text] [Related]
76. Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease. Martínez-Montoro JI; Cornejo-Pareja I; Gómez-Pérez AM; Tinahones FJ Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836332 [TBL] [Abstract][Full Text] [Related]
77. Early life programming of nonalcoholic fatty liver disease in children. Soullane S; Willems P; Lee GE; Auger N Early Hum Dev; 2022 May; 168():105578. PubMed ID: 35489298 [TBL] [Abstract][Full Text] [Related]
78. Factors early in life associated with hepatic steatosis. Quek SXZ; Tan EX; Ren YP; Muthiah M; Loo EXL; Tham EH; Siah KTH World J Hepatol; 2022 Jun; 14(6):1235-1247. PubMed ID: 35978672 [TBL] [Abstract][Full Text] [Related]
79. [Obesity-fatty liver: the role of the pediatrician]. Ciocca M; Álvarez F Arch Argent Pediatr; 2021 Dec; 119(6):427-430. PubMed ID: 34813249 [TBL] [Abstract][Full Text] [Related]
80. Metabolic liver disease - what's in a name? Herman MA Nat Rev Endocrinol; 2021 Feb; 17(2):79-80. PubMed ID: 33257823 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]